Dr. Chen is currently a scientist in the In Vivo Pharmacology / Oncology department at Amgen, at the South San Francisco Site. Amgen's mission is to serve patients and the in vivo pharmacology group is specifically responsible for designing, generating and communicating pharmacology and preclinical data to support the progression of oncology and inflammation research. Dr. Chen investigates and evaluates novel preclinical molecules to support immuno-oncology programs and further drug discovery and development. Dr. Chen's academic background includes a PhD in Biology at University of California San Diego researching effects on the immune microenvironment and cell-intrinsic pathway changes after genetic manipulation murine hepatocellular carcinoma models.